4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in "magic, hallucinogenic mushrooms"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the serotonin transporter (SERT) and psilocybin mainly acts as direct agonist at 5-HT2A receptors. 2C-B interacts with both the 5-HT2A receptor and SERT which is in line with its reported mixed effects profile. However, scientific studies are lacking. There is an increased interest in psychiatric research on the therapeutic properties of MDMA and psilocybin and also on mixed empathogenic-psychedelic substances.

开始日期2023-08-16

申办/合作机构

Universitätsspital Basel

NL8813 / SuspendedN/AIIT

Sub(acute) Neuropsychopharmacological Profiling of 2C-B Versus Psilocybin

开始日期2021-08-04

申办/合作机构

Maastricht University

100 项与 2,5-Dimethoxy-4-bromophenethylamine 相关的临床结果

登录后查看更多信息

100 项与 2,5-Dimethoxy-4-bromophenethylamine 相关的转化医学

登录后查看更多信息

100 项与 2,5-Dimethoxy-4-bromophenethylamine 相关的专利（医药）

登录后查看更多信息

582

项与 2,5-Dimethoxy-4-bromophenethylamine 相关的文献（医药）

2024-12-01·NEUROPHARMACOLOGY

The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model

Article

作者: Heinsbroek, Jasper A. ; Olson, David E. ; Giannotti, Giuseppe ; Kregar, Nathaniel P ; Heinsbroek, Jasper A ; Peters, Jamie ; Bonilla, Joel ; Kregar, Nathaniel P. ; Olson, David E

There has been a recent renewed interest in the potential use of psychedelic drugs as therapeutics for certain neuropsychiatric disorders, including substance use disorders. The psychedelic drug 2,5-dimethoxy-4-iodoamphetamine (DOI) has demonstrated therapeutic efficacy in preclinical models of opioid use disorder (OUD). Alcohol is commonly co-used in individuals with OUD, but preclinical models that recapitulate this comorbidity are lacking. We developed a polydrug model wherein male and female rats were allowed to self-administer intravenous heroin and oral alcohol (or saccharin control solution) over weeks of behavioral training, and then we conducted a series of progressive ratio tests to assess the animals' motivational state for heroin and alcohol. In this model, motivation for heroin is higher than alcohol, and DOI (0.4 mg/kg) administered prior to testing significantly reduced heroin motivation measured as the animals' break point, or maximum effort the animal is willing to expend to obtain a single infusion of heroin. The 5-HT2A receptor antagonist MDL 100,907 (0.3 mg/kg), but not the 5-HT2C receptor antagonist SB-242084 (0.5 mg/kg), blocked the therapeutic effect of DOI on heroin motivation. No significant effects on alcohol break points were observed, nor did MDL 100,907 or SB-242084 have any effect on break points on their own. These data support the view that psychedelic drugs like DOI may have therapeutic effects on opioid use in individuals with OUD and comorbid alcohol use, by acting as a 5-HT2A receptor agonist.

2024-11-06·ACS Chemical Neuroscience

Effects of a Serotonergic Psychedelic on the Lipid Bilayer

Article

作者: Saha Roy, Debsankar ; Mote, Kaustubh R. ; Huster, Daniel ; Maiti, Sudipta ; Vaidya, Vidita A. ; Singh, Ankit

Serotonergic psychedelics, known for their hallucinogenic effects, have attracted interest due to their ability to enhance neuronal plasticity and potential therapeutic benefits. Although psychedelic-enhanced neuroplasticity is believed to require activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT_2ARs), serotonin itself is less effective in promoting such plasticity. Also, the psychoplastogenic effects of these molecules correlate with their lipophilicity, leading to suggestions that they act by influencing the intracellular receptors. However, their lipophilicity also implies that a significant quantity of lipids is accumulated in the lipid bilayer, potentially altering the physical properties of the membrane. Here, we probe whether the serotonergic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) can affect the properties of artificial lipid bilayers and if that can potentially affect processes such as membrane fusion. Solid-state NMR spectroscopy shows that the DOI strongly induces disorder in the lipid acyl chains. Atomic force microscopy shows that it can shrink the ordered domains in a biphasic lipid bilayer and can reduce the force needed to form nanopores in the membrane. Fluorescence correlation spectroscopy shows that DOI can promote vesicle association, and total internal fluorescence microscopy shows that it enhances vesicle fusion to a supported lipid bilayer. While serotonin has also recently been shown to cause similar effects, DOI is more than two orders of magnitude more potent in evoking these. Our results suggest that the receptor-independent effects of serotonergic psychedelics on lipid membranes may contribute to their biological actions, especially those that require significant membrane remodeling, such as neuronal plasticity.

2024-11-01·NEURON

Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI

Article

作者: Kapri, Darshana ; Davoudian, Pasha A ; Karaba, Lindsay A. ; Bath, Kevin G. ; Vuruputuri, Ratna Mahathi ; Chaudhari, Pratik R ; Tiwari, Praachi ; Kwan, Alex C ; Ansorge, Mark S ; Bath, Kevin G ; Vaidya, Vidita A. ; Karaba, Lindsay A ; Balakrishnan, Angarika ; Kwan, Alex C. ; Fernandez-Ruiz, Antonio ; Chaudhari, Pratik R. ; Vaidya, Vidita A ; Ansorge, Mark S. ; Davoudian, Pasha A. ; Zanni, Giulia ; Suryavanshi, Shital ; Sharma, Mukund ; Pradhan, Amartya

There has been a recent renewal of interest in the therapeutic potential of serotonergic psychedelics. Here, we uncover the essential role of ventral hippocampus (vHpc) GABAergic interneurons in the anxiolytic effect evoked by the serotonergic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI). Integrating anatomical, pharmacological, and genetic approaches, we show that 5-HT_2A receptors in the CA1/subiculum (CA1/sub) region of the vHpc are required for the anxiolytic action of DOI. In vivo electrophysiology and opto-tagging experiments indicate that DOI enhances the firing rate of hippocampal fast-spiking parvalbumin (PV)-positive interneurons, most of which express the 5-HT_2A receptors. Restoration of 5-HT_2A receptors in PV-positive interneurons in a loss-of-function background reinstated the anxiolytic responses evoked by DOI in the vHpc CA1/sub region. Collectively, our results localize the acute anxiolytic action of a serotonergic psychedelic to 5-HT_2A receptors in the ventral hippocampus and specifically identify PV-positive fast-spiking cells as a cellular trigger for the psychedelic-induced relief of anxiety-like behavior.

项与 2,5-Dimethoxy-4-bromophenethylamine 相关的新闻（医药）

2024-01-19

·BioSpace

Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence

VANCOUVER, British Columbia, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is pleased to announce it has been granted an amendment to its Health Canada Controlled Drugs and Substances Licence. Effectively implemented on January 16, 2024, the amendment allows substantial increases in the quantities of MDMA, MDA, and 2CB under subsection J.01.059(4) of Part J of the Food and Drug Regulations. Terms of the amendment now permit the following increases: N-METHYL-3,4-METHYLENEDIOXY AMPHETAMINE (MDMA) – from 2kg to 20kg. 3,4-METHYLENEDIOXYAMPHETAMINE (MDA) – from 1kg to 2kg. 4-BROMO-2,5-DIMETHOXYBENZENE ETHANAMINE (2C-B) – from 400g to 4kg. The obtained amendment is a crucial component of Optimi's strategy to solidify its position as an industry-leading psychedelics drug manufacturer, strategically positioning itself in anticipation of the potential approval of MDMA by the U.S. Food and Drug Administration in 2024. Bill Ciprick, Optimi's CEO, underscored the strategic importance of the amendment, stating, "This marks a pivotal achievement in Optimi's strategic licensing plan, positioning us with one of the most robust licensing portfolios globally. It enhances our competitive advantage and perfectly aligns with our vision to be the leading global supplier of GMP MDMA and other psychedelic substances." In its year end Annual Review, the Company laid out its 2024 strategic licensing plan which includes approvals for a Drug Master File (DMF) and Drug Establishment Licence (DEL). This critical documentation affirms Optimi’s commitment to regulatory compliance and transparency, laying the foundation for streamlined communication with regulatory authorities and delivering high-quality APIs and controlled substances that meet global standards for pharmaceutical manufacturing and control. Optimi now has Health Canada approval to manufacture the following controlled substances: 2,5-DIMETHOXYPHENETHYLAMINE 3,4-METHYLENEDIOXYAMPHETAMINE (MDA) 4-BROMO-2,5-DIMETHOXY-N-(2-METHOXYBENZYL)PHENETHYLAMINE (25-BNBOME) 4-BROMO-2,5-DIMETHOXYBENZENE ETHANAMINE (2C-B) 4-CHLORO-2,5-DIMETHOXY-N-(2METHOXYBENZYL)PHENETHYLAMINE(25C-NBOME) 4-HYDROXYBUTANOIC ACID (GHB) 4-IODO-2,5-DIMETHOXY-N-(2-METHOXYBENZYL)PHENETHYLAMINE (25I-NBOME) HARMALINE HARMALOL KETAMINE LYSERGIC ACID DIETHYLAMIDE (LSD) MESCALINE N,N-DIMETHYLTRYPTAMINE (DMT) N-METHYL-3,4-METHYLENEDIOXY AMPHETAMINE PHENCYCLIDINE PSILOCIN PSILOCYBIN SALVINORIN A For media inquiries, please contact Michael Kydd: michaelk@optimihealth.ca For investor inquiries, please contact: investors@optimihealth.ca ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) Optimi Health Corp. an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), natural GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug candidates throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. FORWARD‐LOOKING STATEMENTS This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form dated January 9, 2023, and other continuous disclosure filings available under Optimi’s pro Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

2023-04-20

·BioSpace

Psygen Industries Ltd. Announces Export of LSD to New Zealand and Completion of MDMA Development Program

Calgary, Alberta--(News - April 19, 2023) - Psygen Industries Ltd. (together with its subsidiaries, "Psygen") is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., completed manufacture of more than 1.5 million microdoses of lysergic acid diethylamide ("LSD"). A portion of the LSD has been exported to New Zealand for use in a ground-breaking Phase II clinical trial sponsored by MindBio Therapeutics ("MindBio"). MindBio's clinical trial will provide Psygen's LSD to participants suffering from major depressive disorder for outpatient LSD microdosing in the context of normal daily routines - a first for modern LSD clinical trials. "MindBio's LSD research program holds significant promise for the future of microdose therapies and mental health. Pysgen is proud to be the manufacturer of choice for this medicine that we care so deeply about - discovered eighty years ago today," said Danny Motyka, CEO of Psygen. "LSD is the second API that Psygen has released to the clinical research market after psilocybin, with MDMA and other APIs in Psygen's development pipeline." Psygen is also excited to announce completion of its MDMA development program, including an improved synthetic method. Psygen's operations team is on track to complete GMP validation of MDMA production during the second quarter of 2023. Psygen's MDMA is slated for use as an API in clinical and scientific research around the world. Psygen expects its GMP MDMA will also be available for use in Canada's special access program or other compliant access programs outside of clinical trials. "In light of the proliferation of trauma across the globe, Psygen is proud to help improve global access to medicines that have tremendous potential to heal trauma and inspire creativity. We believe these medicines will play a key role in resolving principal mental health problems facing humanity," says Peter van der Heyden, co-founder and Director of Psygen. At its Calgary facility, Psygen's operations team will advance commercial GMP manufacturing capabilities through validation of synthetic methods for additional psychedelic APIs, as authorized by Psygen's dealer's licence issued by Health Canada. Psygen's goal is to provide high-quality, sustainable, and competitive Canadian-made medicines for the world. Psygen and its team wish everyone a safe and insightful Bicycle Day. About Psygen Psygen is a privately-held licensed dealer and active pharmaceutical ingredient ("API") manufacturer based in Calgary, Alberta. Psygen's dealer's licence authorizes possession, manufacture, sale, import, export and otherwise dealing with LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline. Psygen is positioned to be a leader in manufacturing and sale of synthetic psychedelic APIs for healing and wellness in compliance with applicable laws. Psygen manufactures pharmaceutical-grade psychedelic drug substances in accordance with GMP for clinical research and other therapeutic applications. Psygen's APIs have been sold to, and used by, drug development companies, academic institutions and other authorized persons domestically and internationally. Psygen consists of a team of industry and business experts with over 50 years of direct experience in manufacturing psychedelics. Psygen's team has experience synthesizing an industry-leading variety of psychedelic compounds, including experience manufacturing LSD, psilocybin and MDMA at scale. Psygen's licensed facility is Canada's first dedicated synthetic psychedelics manufacturing facility with authorization for the synthesis of a variety of psychedelic drugs for clinical research and approved therapeutic applications. For more information, please contact: Psygen Industries Ltd. Danny Motyka, CEO Telephone: 403-809-6205 Email: invest@psygen.ca THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit

临床2期

2022-06-16

·PRNewswire

Delic Labs to Present on Psychedelics, Cannabis Extraction at Grow Up Conference and Expo

Dr. Markus Roggen, President and Chief Scientific Officer of Delic Labs, will discuss the advancement of psychedelics as well as improvements of cannabis extraction technology during the Grow Up Conference and Expo in Victoria, British Columbia on June 20-22, 2022. VANCOUVER, BC, June 16, 2022 /PRNewswire/ - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Dr. Markus Roggen, President and Chief Scientific Officer of Delic Labs, and his participation in the upcoming Grow Up Conference and Expo. Dr. Markus Roggen, President and CSO, DELIC Labs (CNW Group/Delic Holdings Inc.) Grow Up Conference and Expo June 20-22, 2022 Held at the Victoria Conference Centre in British Columbia, the Grow Up Conference and Expo is a three-day event featuring workshops and panels led by hundreds of cannabis-industry experts from around the world. Dr. Roggen will be taking part in the following panels: Monday, June 20 Introductions to Psychedelics – An Overview Mitigating Suffering – Can Psychedelic medicine work for you? The Business of Psychedelics in Canada and abroad Tuesday, June 21 Making Extraction more Sustainable Wednesday, June 22 Keeping it consistent - Standardizing your Grow To learn more about the Grow Up Conference and Expo, please visit . In April, Delic Labs received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms, including MDMA, LSD, DMT, mescaline and 2C-B. Additionally, Delic Labs has received a Health Canada 56 exemption to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs' latest exemptions enable the Company to develop innovative analytical methods for psychedelic research. Last year, the lab also applied for a Dealer's License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes. Securing a Dealer's License to accompany its existing research exemptions would cement Delic Labs' position as the leader in psychedelic safety testing. The Company aims to establish consistent quality control standards as more patients and clinicians incorporate psychedelic compounds into treatment plans. About Delic Labs (formerly Complex Biotech Discovery Ventures Ltd.) Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care. About Delic Corp, Inc. Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The Company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses. Forward-Looking Information and Statements This press release contains certain "forward-looking information" within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute "forward-looking ‎statements" within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company's beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic's control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎"plans", ‎‎"expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", ‎‎‎"anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results "may", "could", "would", "might" or "will be ‎taken", "will continue", ‎‎"will occur" or "will be achieved". The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎ By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations. In addition, in connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎ Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎ Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward-looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎ SOURCE Delic Holdings Inc.